AV Ribavirin
| PHA antivirals by mechanism |
32227493 ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19
16621037 2006. (x)Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
32812025 2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
32812051 2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
23594967 2013. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin.
29907366 2019. Uso de ribavirina en virus distintos de la hepatitis C. Una revision de la evidencia.
32711596 2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
32712334 2020. Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study.
32765274 2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
33029193 2020. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
